News

VistaGen licensed exclusive rights of the cardiac stem cell technologies from University Health Network (UHN), Canada's largest research hospital, pursuant to a strategic research agreement with UHN and

Goldfinch was launched with $55m in Series A financing to translate breakthroughs in genetics and kidney biology to lead a new era of therapeutic development targeting the molecular

Ocaliva is a potent and selective agonist of the farnesoid X receptor (FXR), which is expressed at high levels in the liver and intestine and thought to be

The continued treatment with Xtandi , plus abiraterone acetate and prednisone as compared to treatment with abiraterone acetate and prednisone alone, did not meet its primary endpoint of improvement

Actelion said there can be no certainty at this point that any transaction will result. The company said: “No further statement will be made until such time Actelion

The decision follows a pre-planned review of safety data. RHB-104 is an antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. It has

REKOVELLE is the first rFSH to be derived from a human cell line and is the first rFSH treatment to be administered with an individualised dosing regimen. REKOVELLE’s

Proton Partners will invest £30m in its cancer centre which will be located at the Thames Valley Science Park and will offer proton beam therapy among other conventional

Up to 200 new jobs will be created at the Rockville facility, with GSK investing over $50m in the next two years to continue to develop the site